Latest / Pharmacy Podcast Network / Advocating for LTC Pharmacy: Policy Battles & Industry Shifts | FrameworkFocus™
Transcript
- 0:05Speaker 1: You are listening to the global network of podcasters dedicated
- 0:09Speaker 1: to the pharmacy profession. Welcome to the Pharmacy podcast Network.
- 0:31Speaker 2: You are listening to Framework Focus, the podcast that explores trends, innovations,
- 0:36Speaker 2: and insights in the long term care pharmacy industry. Join
- 0:40Speaker 2: us as we connect the entire LTC ecosystem.
- 0:44Speaker 3: Hello, Welcome to the twenty first episode of Framework Focus podcast,
- 0:48Speaker 3: where we explore the latest innovations, challenges, policy shifts shaping
- 0:52Speaker 3: the long term care pharmacy industry. I'm Scott Bady, and
- 0:56Speaker 3: today we're diving into a crucial discussion on advocacy, policy battles,
- 1:01Speaker 3: and the evolving landscape of LTC pharmacy. I'm thrilled to
- 1:05Speaker 3: be joined by a true expert in the field, Alan Rosenbloom,
- 1:09Speaker 3: President and CEO of the Senior Care Pharmacy Coalition. Alan
- 1:13Speaker 3: has been a leading voice for the independent LTC pharmacy community,
- 1:17Speaker 3: working on the front lines to navigate complex regulatory and
- 1:20Speaker 3: legislative landscapes while ensuring patients receive the care they need.
- 1:24Speaker 3: Today's conversation, we're going to explore most pressing policy issues
- 1:28Speaker 3: facing LTC pharmacy. Today. We'll also take a look at
- 1:32Speaker 3: broader industry shifts and discuss reabursement challenges and other issues
- 1:36Speaker 3: facing our pharmacies. There's a lot to cover. Let's jump in.
- 1:40Speaker 3: Alan first, welcome to a framework focus.
- 1:43Speaker 4: Thanks Scott, it's a real pleasure to join you.
- 1:45Speaker 5: I always appreciate the opportunity to talk with you support
- 1:50Speaker 5: Softwriters and its work, and you know, as you know,
- 1:54Speaker 5: a lot of our members are your customers. I'm sure
- 1:56Speaker 5: you'd like more, and so I'm glad I can be
- 1:59Speaker 5: helpful and hopefully spread the word on some of the
- 2:02Speaker 5: challenges we face in Washington and ways that pharmacies and
- 2:06Speaker 5: others can get involved in helping us solve those problems.
- 2:10Speaker 3: Absolutely so, Alan, I met you for the first time
- 2:14Speaker 3: at our Softwriter's user conference in twenty sixteen. You were
- 2:18Speaker 3: asked to speak at that conference. You led a passionate
- 2:21Speaker 3: discussion about the political landscape at that point in time,
- 2:24Speaker 3: and boy, doesn't that seem like a lifetime ago? Twenty
- 2:26Speaker 3: sixteen political.
- 2:28Speaker 4: Landscape general, Yeah, a literal lifetimes ago.
- 2:31Speaker 3: It was a little simpler. So let's start with a
- 2:35Speaker 3: brief introduction. If you wouldn't mind, do you just give
- 2:38Speaker 3: us a little overview of SEPC and your organization's overall
- 2:42Speaker 3: mission sure.
- 2:44Speaker 5: The Senior Care Pharmacy Coalition exists to defend the public
- 2:49Speaker 5: policy interests of long term care pharmacies in Washington at
- 2:52Speaker 5: the federal level, and we are focused on pharmacies as
- 2:55Speaker 5: business operations and dealing with the issues that they face
- 2:59Speaker 5: in the marketplace as they inflect with respect to federal policy.
- 3:04Speaker 5: A lot of this work pertains to Medicare Part D,
- 3:08Speaker 5: primarily in the Part D space payment issues. To a
- 3:11Speaker 5: lesser extent, we will become involved in payment issues associated
- 3:15Speaker 5: with Medicaid, Tricare, federal employee health benefits, and so on.
- 3:20Speaker 5: But as you know, seventy five percent on long term
- 3:23Speaker 5: pair pharmacy revenues come for Medicare Part D, so that's
- 3:26Speaker 5: the heart and soul of that aspect of our work.
- 3:29Speaker 5: Occasionally issues come up with respect to oversight in the FDA,
- 3:33Speaker 5: but those are much less frequent and much less have
- 3:37Speaker 5: much less immediacy in terms of importance for long term
- 3:40Speaker 5: care pharmacies. And you know, we started, as you said,
- 3:43Speaker 5: we met in twenty sixteen. The organization was found in
- 3:46Speaker 5: twenty fourteen, so we're in our tenth eleventh year now.
- 3:51Speaker 5: Which is hard to believe. And we've you know, we've
- 3:55Speaker 5: grown pretty substantially. We've our membership, pharmacy membership has increased
- 3:59Speaker 5: between ten and eleven fold over ten years. Our revenues
- 4:03Speaker 5: have increased between five and six fold over that same
- 4:06Speaker 5: period of time. We've grown a substantial business partner membership
- 4:10Speaker 5: to support us as well, including softwriters, and that is
- 4:15Speaker 5: essential to our success or hopefully success in Washington.
- 4:21Speaker 4: So that's kind of what we do.
- 4:22Speaker 5: And we try to make sure that our members are
- 4:24Speaker 5: not only fully informed and up to date on what
- 4:27Speaker 5: we are doing to try to help them, but also
- 4:30Speaker 5: make sure that they have opportunities to participate and help
- 4:34Speaker 5: us understand what they do translated into the policy world
- 4:39Speaker 5: and try to seek solutions that work for them.
- 4:43Speaker 3: Great, so perfect segue into why don't you give us
- 4:46Speaker 3: a little snapshot into the key priorities for SCPC in
- 4:50Speaker 3: the year ahead.
- 4:51Speaker 5: Sure, number one priority is dealing with a huge problem
- 4:56Speaker 5: that is being created by the negotiated drug prices on
- 4:59Speaker 5: your meda care in twenty because it was in twenty
- 5:03Speaker 5: twenty two Congress passed the Inflation Reduction Act GET a
- 5:07Speaker 5: whole bunch of different things. Part of that was to
- 5:11Speaker 5: empower CMS to negotiate prices for the most expensive brand
- 5:15Speaker 5: named drugs, and that's essentially the drugs that cost.
- 5:19Speaker 4: The federal government the most.
- 5:21Speaker 5: And for the first two years of this program twenty
- 5:23Speaker 5: twenty six and twenty twenty seven, this only applies to
- 5:26Speaker 5: Part D drugs as in David, which is of course
- 5:30Speaker 5: the centerpiece of the long term care pharmacy business. And
- 5:33Speaker 5: when you look at the drugs that are on that
- 5:35Speaker 5: list ten drugs in the first year, about eight of
- 5:40Speaker 5: them are very heavily prescribed to long term care patient
- 5:42Speaker 5: population and are a substantial chunk of both revenues and
- 5:48Speaker 5: margin for long term care pharmacies. As you know, long
- 5:52Speaker 5: term care pharmacies, about ninety percent of the drugs that
- 5:55Speaker 5: data spenser generics about ten percent of brands the.
- 5:58Speaker 4: Generics are around break even.
- 6:00Speaker 5: It kind of depends on how well you purchase, on
- 6:02Speaker 5: what your contracts are as to whether you do a
- 6:04Speaker 5: little bit better than break even or a little bit
- 6:06Speaker 5: worse than break even on ingredient costs. But you don't
- 6:09Speaker 5: run your business on the margin that you get from brands.
- 6:12Speaker 5: Either way, Dispensing fees are way lower than costs. Last
- 6:17Speaker 5: year we commissioned Clifford Larson Allens to do a study
- 6:21Speaker 5: of what it actually costs to meet the requirements that
- 6:24Speaker 5: long term that are imposed on long term care pharmacies,
- 6:27Speaker 5: and it average is about fifteen dollars a prescription that
- 6:29Speaker 5: a matter of course, whether it's Generica brand, that's what
- 6:32Speaker 5: it costs. Part D plans on average pay about four dollars.
- 6:35Speaker 5: So every time a prescriptions dispensed, you're losing eleven dollars
- 6:39Speaker 5: is compared to your costs to dispense. So you make
- 6:42Speaker 5: it up on brand margin and with the MFP or
- 6:45Speaker 5: negotiated price maximum fair price. These are the negotiated that's
- 6:49Speaker 5: the term of art for the negotiated prices. With those
- 6:53Speaker 5: negotiated prices, which is the most that a Part D
- 6:57Speaker 5: plan can pay for ingredient.
- 6:58Speaker 4: Cost reimbursement of eviscerates the market.
- 7:02Speaker 5: You know, we estimate that you know, for the average
- 7:05Speaker 5: long term care pharmacy operating margin that is EBITDA effectively
- 7:11Speaker 5: is going to be thirty percent lower. And that's obviously
- 7:15Speaker 5: before you do capital you know, capex reinvestment, before you
- 7:18Speaker 5: invest in growth, before you pay your taxes, before you
- 7:21Speaker 5: do your debt service and before you're hopefully left with something.
- 7:23Speaker 4: At the at the end.
- 7:24Speaker 5: At the end of all of that, that's a pretty
- 7:26Speaker 5: devastating loss for long term care pharmacies. And you know,
- 7:30Speaker 5: coming right on the heels of that or that now
- 7:31Speaker 5: we know what the fifteen drugs that have been announced
- 7:35Speaker 5: for twenty twenty seven are. We don't know what the
- 7:37Speaker 5: negotiated prices are, but those are also very heavily prescribed,
- 7:41Speaker 5: ten of them in long term care. And we estimate
- 7:44Speaker 5: that the impact of that ballpark, because we don't know
- 7:46Speaker 5: exactly until we know the prices, is going to be
- 7:49Speaker 5: about forty percent of the impact in twenty twenty six.
- 7:55Speaker 5: So you're looking at you know, a thirty percent margin
- 7:58Speaker 5: hit in the first year, in a ten percent to
- 8:00Speaker 5: twelve percent marchin hit in the next year. That's that's
- 8:04Speaker 5: devastating for this sector. And so that is our primary focus.
- 8:09Speaker 3: And talk a little bit about how the new presidential
- 8:12Speaker 3: administration impacts, you know, this Inflationary Reduction Act or just
- 8:17Speaker 3: broader pharmacy policy as we see it, How does that
- 8:20Speaker 3: differ from that previous administration.
- 8:23Speaker 4: To be honest, we don't know yet.
- 8:26Speaker 5: You know, a lot of the focus of the Trump
- 8:29Speaker 5: administration and the Republican Congress right now is on extending
- 8:34Speaker 5: and making permanent tax cuts from twenty seventeen, which will
- 8:38Speaker 5: cost a lot of money, and so the focus is
- 8:41Speaker 5: more on where do we cut across a whole spectrum
- 8:45Speaker 5: while protecting Medicare. You know, President made a promise that
- 8:50Speaker 5: this wouldn't affect Medicare, and Congress is trying to keep
- 8:53Speaker 5: that promise. We'll see if it actually works out in
- 8:56Speaker 5: terms of healthcare policy. That is just at the administrative level.
- 9:00Speaker 5: They're just hints because it's clear the administration's focuses elsewhere.
- 9:04Speaker 5: So RFK Junior and his confirmation hearings essentially said that
- 9:10Speaker 5: they plan to continue the IRA drug price negotiation program
- 9:15Speaker 5: as is. They may have some little tweaks behind the scenes.
- 9:19Speaker 5: Having said that, there's a lot going on in this space,
- 9:22Speaker 5: because putting aside this long term care pharmacy specific issue
- 9:26Speaker 5: that I've described, there are a whole bunch of implementation
- 9:29Speaker 5: problems and costs that pharmacies are going to have to
- 9:32Speaker 5: bear as a result, which is occupying a lot of
- 9:36Speaker 5: oxygen to see whether or not in the pharmacy space,
- 9:39Speaker 5: to see whether or not the administration or CMS could
- 9:42Speaker 5: do something a little bit differently in terms of implementation
- 9:45Speaker 5: to improve the situation.
- 9:47Speaker 4: There are some calls to delay.
- 9:49Speaker 5: Implementation, and as you may have seen in recent days,
- 9:55Speaker 5: pharma pharma executives met with the President, and our understanding
- 10:01Speaker 5: of what they want with respect to the IRA is
- 10:04Speaker 5: some changes in some of those internal decisions that the
- 10:07Speaker 5: administration can make, which would mean effectively that drugs would
- 10:11Speaker 5: be the high high profit drugs would somehow get delayed
- 10:16Speaker 5: in getting on the negotiated price you know, schedule, rather
- 10:22Speaker 5: than stopping the thing or trying to reverse the thing.
- 10:24Speaker 5: And the problem with any effort to stop it or
- 10:27Speaker 5: repeal it is that it costs a lot of money
- 10:29Speaker 5: from the federal budget perspective, which makes it difficult, and
- 10:33Speaker 5: that's not.
- 10:33Speaker 4: What they're focused on.
- 10:34Speaker 5: So you can probably tell that just from the news
- 10:37Speaker 5: media reports that healthcare is not at the top of
- 10:40Speaker 5: the agenda. Now you will hear references to the IRA,
- 10:44Speaker 5: But the IRA had a whole bunch of other stuff
- 10:46Speaker 5: in it. It wasn't just the Medicare drug pricing provisions
- 10:50Speaker 5: and the restructuring of Part D. It was also climate
- 10:54Speaker 5: you know up you know, uh, climate change policies and
- 10:58Speaker 5: other kinds of policy is that the Republicans are anxious
- 11:02Speaker 5: to repeal, but there's not there's no talk at all
- 11:05Speaker 5: about trying to deal with with you know, the I
- 11:08Speaker 5: or A drug pricing provisions at this point, at least
- 11:11Speaker 5: in terms of big picture policy change.
- 11:14Speaker 3: Understood, and just to give the group our listeners a
- 11:17Speaker 3: bit of a better perspective. I know from participating in
- 11:20Speaker 3: SPC you have deep relationships across both sides of the aisle,
- 11:24Speaker 3: and your advocacy efforts are pretty wide reaching across you know,
- 11:29Speaker 3: the Congress and multiple members of different healthcare committees. You
- 11:34Speaker 3: just talk a little bit about that so that the
- 11:36Speaker 3: audience understands your focus is not just a small group
- 11:39Speaker 3: of people that just changed out as it relates to
- 11:42Speaker 3: the presidential administra journey.
- 11:44Speaker 5: Yeah, you know, I'd be happy to do that, and
- 11:47Speaker 5: I appreciate the opportunity because if you are, you know,
- 11:50Speaker 5: in the Washington environment, if you're trying to drive policy changes,
- 11:54Speaker 5: which is of course what we're trying to do, you
- 11:57Speaker 5: have to be good at at a series of things.
- 12:00Speaker 5: So one of the things you need to be good
- 12:01Speaker 5: at is lobbying. It is directly talking to members of Congress,
- 12:06Speaker 5: about the issues of the issues that are concerned to
- 12:09Speaker 5: you and persuade them that what you're trying to accomplish
- 12:13Speaker 5: is what they ought to try to support. Right For example,
- 12:16Speaker 5: I mentioned this drug pricing situation, and because of all
- 12:19Speaker 5: of the political dynamics, you know, the need to reduce
- 12:23Speaker 5: spending in certain arenas, the fact that our proposal is
- 12:25Speaker 5: going to cost a little bit of money however you
- 12:28Speaker 5: do it, and trying to figure that out.
- 12:30Speaker 4: We've decided that.
- 12:31Speaker 5: You know, this year's strategy has lived to fight another day,
- 12:35Speaker 5: So we're trying to get a two year solution, which
- 12:39Speaker 5: for the drugs that are subject to negotiated prices, would
- 12:42Speaker 5: mean that pharmacies long term care pharmacist will get an
- 12:45Speaker 5: additional supply fee over and above whatever the negotiated dispensing
- 12:50Speaker 5: fee is and whatever the negotiate an ingredient cost reimbursement is.
- 12:54Speaker 5: And we calculated that based on what we think if
- 12:58Speaker 5: you take all the risks into a count that we
- 13:01Speaker 5: bear and have no control over the amount that we
- 13:05Speaker 5: think would fill that hole, and that will allow us
- 13:08Speaker 5: a little bit of breathing space to deal with a
- 13:11Speaker 5: longer term solution that is more sensible than just keep
- 13:16Speaker 5: keeping bandaids on the system. So I provide that as
- 13:19Speaker 5: context because now let's talk about what you asked, which
- 13:22Speaker 5: is political relationships.
- 13:23Speaker 4: How do we do that. We have to look at the.
- 13:25Speaker 5: Political reality today, which is, of course, the Republicans control
- 13:28Speaker 5: every chamber. They're both the Senate and the House. They've
- 13:31Speaker 5: got the White House. But as you can see, the
- 13:34Speaker 5: Republicans are not unified. You know, they want to do
- 13:38Speaker 5: what's known as reconciliation. And reconciliation is basically a technique
- 13:42Speaker 5: that gets around the fact that most things in the
- 13:45Speaker 5: Senate have to pass by sixty votes, right, because there
- 13:49Speaker 5: are fifty three Republicans, and that would mean that whatever
- 13:52Speaker 5: gets considered and passed would have to have at least
- 13:55Speaker 5: seven Democrats voting for it.
- 13:57Speaker 4: And many of the things, especially the extension.
- 13:59Speaker 5: Of the these tax cuts that the Republicans would like
- 14:03Speaker 5: to see, the Democrats are just never going to vote
- 14:05Speaker 5: for right plus because of the way President Trump is.
- 14:11Speaker 4: Acting unilaterally.
- 14:14Speaker 5: Whatever you think of that, the Democrats are less and
- 14:17Speaker 5: less and less and less and less likely to cooperate
- 14:20Speaker 5: because they feel that the president is overreaching and exceeding
- 14:25Speaker 5: his congressional his constitutional authority. And frankly, behind the scenes
- 14:29Speaker 5: there are some Republicans who agree but are not going
- 14:30Speaker 5: to say that publicly.
- 14:32Speaker 4: So in that environment, what do we do? Oh.
- 14:35Speaker 5: The one thing I also want to mention about reconciliation
- 14:37Speaker 5: is that the trick about reconciliation is that it only
- 14:40Speaker 5: applies to the budgetary process. So anything that gets into
- 14:44Speaker 5: a reconciliation bill, theoretically at least has to be driven
- 14:49Speaker 5: by impact on the budget rather than by the policy
- 14:53Speaker 5: objectives that is honored in the breach in very significant measures.
- 14:56Speaker 5: But parliamentarily, in of the Senate get to decide, and
- 15:01Speaker 5: you can expect that the Democrats, if they don't like
- 15:03Speaker 5: policies that are in this reconciliation bill or package or
- 15:07Speaker 5: whatever they come up with, will be challenging all of
- 15:10Speaker 5: those and there will be parliamentarian rulings that could kick
- 15:13Speaker 5: things out. So that's kind of the dynamic. So our
- 15:16Speaker 5: first cut opportunity to get our solution is to try
- 15:19Speaker 5: to get it into reconciliation, which is of course all Republicans,
- 15:23Speaker 5: because frankly, no Democrat is going to vote for reconciliation.
- 15:27Speaker 5: And in order to do that, we've got to have
- 15:29Speaker 5: relationships with members of Congress at the at the kind
- 15:32Speaker 5: of rank and file level, people who are on committees
- 15:36Speaker 5: but are not in leadership of committees or not in
- 15:38Speaker 5: overall leadership, and we.
- 15:41Speaker 4: Have those kinds of relationships.
- 15:43Speaker 5: There are people like on the Republican side of the isle,
- 15:46Speaker 5: Morgan mcgriffith from Virginia, Diana Harschberger from Tennessee, Adrian Smith
- 15:54Speaker 5: from Nebraska.
- 15:55Speaker 4: And so on.
- 15:55Speaker 5: On the Democratic side of the aisle Branch Niter from Illinois,
- 16:00Speaker 5: you know, and a few others.
- 16:01Speaker 4: I'm just giving these.
- 16:02Speaker 5: Examples to say, rank and file, we've got to have
- 16:05Speaker 5: relationships there. We have relationships at the lobbying level. We
- 16:08Speaker 5: also have relationships at the grassroots level, because you know,
- 16:12Speaker 5: elected officials care about a couple of things, but the
- 16:14Speaker 5: things they care about the most are am I going
- 16:17Speaker 5: to get re elected?
- 16:18Speaker 4: So votes?
- 16:20Speaker 5: And do I have enough money to run my campaign?
- 16:23Speaker 5: So political contributions. And I mentioned that there are four
- 16:26Speaker 5: or five domains that you have to be good at.
- 16:28Speaker 5: One of them is the lobbying and that is at
- 16:30Speaker 5: the grassroots at the ranked file level. That's at the
- 16:33Speaker 5: committee leadership level. So the committee that has primary jurisdiction
- 16:38Speaker 5: over medicare party is the Energy and Commerce Committee. The
- 16:42Speaker 5: chairman is Brett Guthrie from Kentucky. He's somebody we have
- 16:45Speaker 5: very good relationship with. And the Health Subcommittee and the
- 16:48Speaker 5: chair there is Representative Buddy Carter from Georgia, pharmacist, former
- 16:52Speaker 5: long term care pharmacy owner. Many people who will be
- 16:55Speaker 5: listening to this probably know him personally and he is
- 16:58Speaker 5: a real ally for us. That's kind of the way
- 17:00Speaker 5: we work relationships. And then of course Leadership Speaker Johnson
- 17:05Speaker 5: is primarily the person we need to deal with, and
- 17:09Speaker 5: we are. In fact, we have a series of meetings
- 17:11Speaker 5: in a couple of weeks, including a a sit down
- 17:14Speaker 5: with Speaker to try to explain this in more detail.
- 17:16Speaker 5: We've talked to him about it a few times and
- 17:19Speaker 5: hopefully get his commitment to help us fix the problem.
- 17:23Speaker 5: So that's that's the main Number one. I'll stop there
- 17:26Speaker 5: because I can talk about the other domains because they're complimentary.
- 17:29Speaker 5: But I don't know if you want me to go
- 17:30Speaker 5: there now you want hitting it infer direction?
- 17:32Speaker 3: No, I think that's great. Look, it's important I think
- 17:35Speaker 3: for our listeners to understand the breadth and the depth
- 17:38Speaker 3: of the work that you do at SCPC. As it
- 17:41Speaker 3: relates to this advocacy work, because it takes years to
- 17:43Speaker 3: build and sustain these relationships, and you obviously have situations
- 17:47Speaker 3: where there's turnover in certain seats, and so your efforts
- 17:52Speaker 3: to ensure that the continuity of the progress you're making
- 17:57Speaker 3: and the advocacy work doesn't stop with seems changing. Right.
- 18:01Speaker 4: Yeah, Yeah, it's not just it's not just members of
- 18:03Speaker 4: Congress changing.
- 18:04Speaker 5: It's the staff changing, because most of the work you
- 18:06Speaker 5: do is actually with staff, you know, and you develop
- 18:09Speaker 5: these relationships and folks move around, so over time that helps.
- 18:13Speaker 5: But in the short term, yeah, it's a constant re
- 18:15Speaker 5: education process. Most people on the Hill when we started,
- 18:18Speaker 5: and this is one of the reasons as EPC started,
- 18:20Speaker 5: there was one and I mean this necessarily one member
- 18:23Speaker 5: of Congress who understood long term care farmacy, understood that
- 18:26Speaker 5: it was different from retail pharmacy. Now it's Buddy Carter
- 18:29Speaker 5: and it's time. Most people did not know what a
- 18:32Speaker 5: PDM was, I mean members of Congress, right, So part
- 18:36Speaker 5: of part of our mission was to help the fight
- 18:39Speaker 5: on PBMs, and an important part of our mission was
- 18:42Speaker 5: getting people to understand what long term care pharmacies are,
- 18:46Speaker 5: how they differ and why policies need to be inflected
- 18:49Speaker 5: differently to make sense for us. And now a lot
- 18:55Speaker 5: more people know what long term care pharmacy is and
- 18:57Speaker 5: understand that there needs to be these There need to
- 18:59Speaker 5: be the kind of policy inflections, and some of the
- 19:02Speaker 5: PBM reform legislation that is pending reflects.
- 19:05Speaker 4: Those flex that success.
- 19:06Speaker 5: We got a long way to go, and so to
- 19:09Speaker 5: come back, I talked about the direct lobbying. That's me
- 19:12Speaker 5: and we have a very strong group of contract lobbyists.
- 19:16Speaker 5: One of our one or two of our members have
- 19:18Speaker 5: internal corporate lobbyists and we coordinate that.
- 19:23Speaker 4: We also to the extent we can.
- 19:24Speaker 5: Partner with other organizations that are that have that are
- 19:28Speaker 5: like minded in terms of their objectives.
- 19:31Speaker 4: We have a grassroots.
- 19:32Speaker 5: Program and this is where you know pharmacies can really
- 19:36Speaker 5: be helpful and pharmacists can really be helpful because the
- 19:40Speaker 5: more we can connect the dots to people who are
- 19:42Speaker 5: in the communities that the members of Congress serve, the
- 19:47Speaker 5: more likely we are to be able to leverage the
- 19:49Speaker 5: combination of what we're doing in Washington and that and
- 19:53Speaker 5: some other things, and that those those local relationships to
- 19:57Speaker 5: drive policy change.
- 19:59Speaker 4: U and that's kind of a challenge for long term.
- 20:02Speaker 5: Care pharmacies because you know, there's not a long term
- 20:05Speaker 5: care pharmacy in every congressional district in the country, but
- 20:08Speaker 5: people who need long term care are being served by
- 20:11Speaker 5: long term care pharmacies in every congressional district in the country.
- 20:15Speaker 5: And so you know, this grassroots stuff builds over time
- 20:19Speaker 5: and becomes part of the part of the equation. It's
- 20:22Speaker 5: important to have facts in Washington. Everybody has has, you know,
- 20:26Speaker 5: analytics and so on, and that's a big part of
- 20:28Speaker 5: what we do is to make sure that we have
- 20:31Speaker 5: the research capacity through third party relationships to make the
- 20:37Speaker 5: kind of statements I made today. And this you know
- 20:39Speaker 5: in this conversation, like the fact that the impact of
- 20:42Speaker 5: the negotiated price drugs in twenty twenty six will you know,
- 20:46Speaker 5: on average mean thirty percent reduction in operating margins, right,
- 20:51Speaker 5: because when I go into talk to a member of Congress,
- 20:53Speaker 5: we have credible data and it says that the Finally,
- 20:56Speaker 5: there are two other pieces of the puzzle.
- 20:57Speaker 4: I'll just mention them quickly. One is Communica.
- 21:00Speaker 5: You've got to be able to get your message out
- 21:03Speaker 5: and we have a pretty good function there we'd like
- 21:06Speaker 5: to strengthen that, to be honest, and we're in the
- 21:07Speaker 5: process of doing that. And then finally, unfortunately political action.
- 21:12Speaker 5: I mentioned money earlier. Members of Congress respond and sometimes
- 21:17Speaker 5: the easiest way to tee up an issue is at
- 21:20Speaker 5: a fundraiser. Now, you don't get you know, it's not
- 21:22Speaker 5: like a quid pro quo. It's not like you contribute
- 21:24Speaker 5: and you get what you want. But it does give
- 21:26Speaker 5: you a forum to just talk about one issue for
- 21:31Speaker 5: an extended period of time with a member of Congress
- 21:33Speaker 5: and then feed that back into the whole process, meeting
- 21:37Speaker 5: with the staff, building from the staff to other members
- 21:40Speaker 5: of Congress, getting gressed, getting you know, constituents to say
- 21:43Speaker 5: this is a problem, can you help us fix it?
- 21:46Speaker 5: And then you know, kind of coordinating all of that
- 21:49Speaker 5: into a dedicated campaign, which is what we are doing
- 21:53Speaker 5: right now on this on this drug pricing issue in particular.
- 21:57Speaker 3: Right, so, as you talk about the success of grassroots
- 22:00Speaker 3: efforts and communications required, a big part of that is
- 22:03Speaker 3: demystifying a really complex set of set of circumstances, right,
- 22:08Speaker 3: the second and third order effects, unintended consequences of the
- 22:11Speaker 3: legislative actions, and so you just talk a little bit
- 22:14Speaker 3: about the Safe Senior Care RX and just yeah, that's
- 22:17Speaker 3: attempting to do. And then I do want to talk
- 22:19Speaker 3: about PBMs, which is you said, that's where the organizations
- 22:21Speaker 3: started and we're still very much fighting that battle, so
- 22:24Speaker 3: we want to dig.
- 22:26Speaker 4: Yeah.
- 22:26Speaker 5: Yeah. So so the Safe Senior or campaign we launched
- 22:32Speaker 5: last summer because of this drug pricing issue and because
- 22:36Speaker 5: we were hoping that other organizations would join us in
- 22:40Speaker 5: this fight, and that was the vehicle for for for
- 22:45Speaker 5: you know, kind of allowing people to participate without necessarily.
- 22:48Speaker 4: Being SEPC members.
- 22:51Speaker 5: And now that we and we're now actually next week
- 22:55Speaker 5: there's going to be a meeting in DC to try
- 22:57Speaker 5: to really get some partners active in that campaign and
- 23:02Speaker 5: supportive of the campaign, which is designed to get the
- 23:04Speaker 5: same solution that I've already described to but to be
- 23:07Speaker 5: a forum for a coalition to help support it, right,
- 23:11Speaker 5: And that's what that's what the campaign's about, whether it's
- 23:13Speaker 5: through SEPC directly just uniquely on behalf of long term
- 23:18Speaker 5: care pharmacies in our membership, or you know this broader
- 23:21Speaker 5: group that we hope will have uh, you know, advocacy
- 23:26Speaker 5: groups for patients and for for people who need long
- 23:29Speaker 5: term care. Other pharmacy groups, facility based groups like the
- 23:32Speaker 5: American Healthcare Association, which has been a very good partner
- 23:35Speaker 5: for us. And you talk about second order effects and
- 23:38Speaker 5: third order effects, you know, one of the if this
- 23:41Speaker 5: problem doesn't get fixed. Of course, long term care pharmacies
- 23:44Speaker 5: face a very very very difficult economic situation for everybody.
- 23:49Speaker 4: It's a material it's a material risk.
- 23:51Speaker 5: For smaller pharmacies or companies that have pharmacies in rural areas,
- 23:57Speaker 5: it's an existential risk. Uh, you know, and I really
- 24:02Speaker 5: don't see how small pharmacies serving rural facilities survive. And
- 24:06Speaker 5: I don't see companies that have a multiple pharmacies but
- 24:09Speaker 5: that have pharmacies in rural areas will keep those open.
- 24:12Speaker 4: So what are the second order effects those?
- 24:15Speaker 5: You know, if they're skilled nursing facilities, they can't get
- 24:19Speaker 5: their drugs from a retail pharmacy. The residents can't get
- 24:22Speaker 5: their drugs from mail order that pharmacy, that facility closes,
- 24:26Speaker 5: period to closes. Now, that's not going to be a
- 24:28Speaker 5: huge it's not going to be twenty percent of the sector,
- 24:30Speaker 5: but it's some subset of the sector is going to
- 24:32Speaker 5: have that kind of problem for the rest of the facilities,
- 24:36Speaker 5: pharmacies are going to need more on the Part eight side,
- 24:39Speaker 5: and we estimate that at minimum that's a twenty five
- 24:42Speaker 5: percent increase in facility drug spend front Part A, which
- 24:47Speaker 5: facilities are not thrilled about, right, So we're hoping that
- 24:49Speaker 5: they will partner with us because of that. Similarly, for patients,
- 24:54Speaker 5: access will diminish those rural areas for example, and services
- 24:58Speaker 5: will either become all the car or less frequent, so
- 25:01Speaker 5: they'll be less frequent deliveries, you know, and and so forth,
- 25:05Speaker 5: and that can lead to you know, patient patients not
- 25:09Speaker 5: getting the drugs when they need them, drug complications that
- 25:12Speaker 5: could have been avoided, unnecessary hospitalizations, et cetera.
- 25:16Speaker 3: And when you talk about even a small percentage of
- 25:19Speaker 3: facilities closing, when you look at the demographics and the
- 25:22Speaker 3: increasing patient populations that need to be served through long
- 25:26Speaker 3: term care, even a small percentage of facility closures would
- 25:30Speaker 3: be a significant issue.
- 25:32Speaker 5: Yeah, I think so it depends in the area, right
- 25:35Speaker 5: because you know, if you look at on the facility side,
- 25:38Speaker 5: right before COVID, occupancy was in the low eighty percents,
- 25:43Speaker 5: and that was you know, for some that was break
- 25:46Speaker 5: even for some it was it was it was you know,
- 25:48Speaker 5: they were they were doing you know better.
- 25:51Speaker 4: COVID devastated facilities.
- 25:53Speaker 5: The occupancy has been slow to come back up, primarily,
- 25:57Speaker 5: I think due to staffing problems. Can't get the stay
- 26:00Speaker 5: so you can't fill the beds, and it seems to
- 26:05Speaker 5: be back kind of to a reasonable level now. So
- 26:09Speaker 5: while there is capacity, there's some areas where there is
- 26:11Speaker 5: no capacity, and that's where you're going to have these problems.
- 26:15Speaker 3: Right, So, ultimately, what we're talking about is underlying financial
- 26:20Speaker 3: hardship created by some of these programs, legislative evolutions as
- 26:26Speaker 3: well as the PBMs. So let's let's dig into that
- 26:29Speaker 3: a little bit. I want to sort of hear from you.
- 26:31Speaker 3: You know that this is a really core issue, and
- 26:34Speaker 3: so can you just talk a little bit about how
- 26:36Speaker 3: PBMs are impacting LTC pharmacies and what reforms are currently
- 26:41Speaker 3: being evaluated or proposed at the federal level.
- 26:44Speaker 4: Sure, sure, Well, you know.
- 26:46Speaker 5: At PBMs impact long term care pharmacies, you know, in
- 26:52Speaker 5: ways that are similar to all pharmacies. So it's a
- 26:55Speaker 5: constant financial squeeze essentially, right, always onward pressure on payments,
- 27:01Speaker 5: downward pressure on dispensing fees, downward pressure on uh you know,
- 27:06Speaker 5: on ingredient cost reimbursement, both on the generic side and
- 27:09Speaker 5: the brand side.
- 27:10Speaker 4: Uh and and and then all of the additional fees
- 27:14Speaker 4: that come up that you get charged, not.
- 27:17Speaker 5: Just simple switch fees or transaction fees, which it's reasonable
- 27:20Speaker 5: that a PBM gets, you know, you know, a flat
- 27:23Speaker 5: transaction fee for processing a claim. That that seems and
- 27:27Speaker 5: that was the original idea. But because of the the
- 27:31Speaker 5: ability to control formulais that's created, you know, and that's
- 27:35Speaker 5: created the power, if you will, that PBM's wield, and
- 27:39Speaker 5: then that is what attracts. That's why they consolidated. That's
- 27:42Speaker 5: why they became part of mega you know, mega corporations
- 27:46Speaker 5: like CBS and.
- 27:47Speaker 4: UH you know UH United in uh es, you know,
- 27:53Speaker 4: SIGNA and so on, and.
- 27:55Speaker 5: So the disproportion of market power just continues to you know,
- 27:59Speaker 5: it's like a blue right squeeze the balloon, so you
- 28:02Speaker 5: get a look like one of the other reasons SEPC
- 28:05Speaker 5: formed is that there were no grs on generics at
- 28:09Speaker 5: the time that SEPC came together, and you know, the
- 28:12Speaker 5: the and the generic rate was just plummeting. Ninety percent
- 28:16Speaker 5: of scripts are generic and long term care pharmacies needed separate,
- 28:19Speaker 5: separate representation to deal with that. We got some things
- 28:22Speaker 5: done in Washington that I think helped the p SAOs
- 28:26Speaker 5: negotiate contracts that ad grs in them. Well over time,
- 28:29Speaker 5: the grs have eroded, the PBMs are not you know,
- 28:33Speaker 5: are not reconciling fairly at the end of the year
- 28:37Speaker 5: to actually get to the geers, you know, And and
- 28:40Speaker 5: so that's one of the I think one of the
- 28:42Speaker 5: pressure points right going forward. One of the concerns is
- 28:46Speaker 5: what happens with the MFP price that, you know, the
- 28:50Speaker 5: negotiated prices.
- 28:51Speaker 4: Because.
- 28:53Speaker 5: The negotiated prices also mean reduced rebates for PBMs and plans,
- 29:00Speaker 5: so their economics change. When their economics change, how does
- 29:04Speaker 5: that filter down to long term care pharmacies. And you know,
- 29:07Speaker 5: contract negotiations with twenty twenty six are kind of already
- 29:11Speaker 5: underway for some of the bigger companies, they're probably close
- 29:14Speaker 5: to resolution. For the psaos and the smaller companies or
- 29:18Speaker 5: mid sized companies that negotiate through them, it's going to
- 29:21Speaker 5: take a little longer to get the contracts done. But
- 29:24Speaker 5: you know, the plans are saying we're going to look,
- 29:25Speaker 5: we're going to lose big rebate dollars in twenty twenty six.
- 29:29Speaker 5: Even though they will try to manipulate the formal at formularies,
- 29:32Speaker 5: you know, to shift that's not always going to be possible.
- 29:35Speaker 5: And so is that how is that going to put
- 29:38Speaker 5: pressure on the long term care pharmacies because remember the
- 29:44Speaker 5: ingredient cost reimbursement for those negotiated price drugs.
- 29:48Speaker 4: Has a ceiling but not a floor.
- 29:50Speaker 5: Plans can't pay more than the negotiated price, but they
- 29:54Speaker 5: can pay less, and we don't know yet whether that
- 29:58Speaker 5: will be a pressure point. Well, they try to put
- 30:01Speaker 5: more pressure on dispensing fees. I do think one of
- 30:03Speaker 5: the things you're seeing is that plans are less willing
- 30:07Speaker 5: and PBMs are less willing to pay higher dispensing fees
- 30:11Speaker 5: for long term care pharmacy services in settings outside skilled nursing,
- 30:16Speaker 5: so in assisted living in the community. You know, it
- 30:19Speaker 5: used to be that in assisted living you'd get a
- 30:21Speaker 5: higher dispensing fee, although it wouldn't be the sniff dispensing fee,
- 30:25Speaker 5: and to some degree you might get a little bit
- 30:27Speaker 5: more in community. I think that plans are simply moving
- 30:30Speaker 5: away from that because they don't legally have to do that,
- 30:33Speaker 5: So why wouldn't they, Right, it's money in their pockets
- 30:36Speaker 5: or in long term care pharmacy's pockets, and if their
- 30:38Speaker 5: economics are going south, they're going to pass it along.
- 30:41Speaker 4: They're going to pass the pain along.
- 30:42Speaker 5: So that I think is our biggest immediate PBM concern,
- 30:45Speaker 5: as well as all of the things that have been
- 30:47Speaker 5: out there forever, the abusive practices, the predatory audits, you know,
- 30:53Speaker 5: the overall predatory behavior, the you know, the failure to
- 30:59Speaker 5: meet contract actual terms and basically say sue us because
- 31:02Speaker 5: they've got much deeper pockets than we do. All of
- 31:06Speaker 5: those things are out there. So how does that play
- 31:08Speaker 5: into the pending legislation? And as you probably know, last year,
- 31:14Speaker 5: there was a kind of a deal at the end
- 31:16Speaker 5: of the year for Congress.
- 31:18Speaker 4: To get out of town. It included PBM reform in it.
- 31:22Speaker 5: Elon Musk blew that up, you know, he complained about
- 31:25Speaker 5: the debt ceiling, and then President Trump or then President
- 31:29Speaker 5: elect Trump jumped on the bandwagon.
- 31:31Speaker 4: House Republicans, you know, cowered in fear.
- 31:35Speaker 5: Suddenly the plan blew up, the second plan blew up,
- 31:38Speaker 5: and ultimately the PBM reform stuff got dropped off the table.
- 31:41Speaker 5: There is a lot of pressure to get it back
- 31:43Speaker 5: on the table and into something this year. Probably not
- 31:49Speaker 5: the Reconciliation package, although it's possible because it saves money,
- 31:54Speaker 5: but maybe something at the end of the year. And
- 31:58Speaker 5: Buddy Carter, who I mentioned, Brett Guthrie, Jamie Comer as
- 32:01Speaker 5: a House member from Kentucky, chair of the Oversight Committee.
- 32:05Speaker 5: These are relatively powerful folks who really want to get
- 32:08Speaker 5: this done and are doing things in Washington to try
- 32:10Speaker 5: to get it done. So let's talk about what's in
- 32:12Speaker 5: that package, because it's probably going to be what was
- 32:14Speaker 5: in the year end package last year. I don't think
- 32:16Speaker 5: there's going to be a lot of ads. And that
- 32:19Speaker 5: itself was a compromise between the Senate and the House
- 32:22Speaker 5: that kind of took out some very good provisions with
- 32:26Speaker 5: respect to Part D, and so if on the Part
- 32:28Speaker 5: D side, I would say that what they're what they're
- 32:31Speaker 5: that package contained was kind of you know, B minus
- 32:35Speaker 5: reforms B minus C plus. It was a lot of disclosure,
- 32:39Speaker 5: but a lot of the disclosure ran from the PBMs
- 32:41Speaker 5: to the plans, which is kind of like talking to
- 32:45Speaker 5: yourself in most cases, so it wasn't clear that that
- 32:47Speaker 5: how that was going to make a lot of change.
- 32:51Speaker 5: But so on part D, you know, it was kind
- 32:54Speaker 5: of like I said, B minus on Medicaid. However, even
- 33:00Speaker 5: though that's only a small percentage of our business, there
- 33:02Speaker 5: was something.
- 33:03Speaker 4: In there that would be very valuable. And essentially it
- 33:06Speaker 4: would have required that.
- 33:12Speaker 5: Medicaid managed care pay the same dispensing fees as Medicaid
- 33:16Speaker 5: fee for service. And to give you an example in
- 33:20Speaker 5: the retail context, the average Medicare dispensing Medicaid dispensing.
- 33:24Speaker 4: Fee and the fee for service side.
- 33:26Speaker 5: This is for everybody, you know, because the way they
- 33:28Speaker 5: do they do it so this is long term care
- 33:29Speaker 5: and retail was.
- 33:31Speaker 4: About ten to fifty the average dispensing fee.
- 33:35Speaker 5: Actually, just right before this call, right before we started talking,
- 33:39Speaker 5: I was in a discussion with our analysts on what
- 33:42Speaker 5: Medicaid managed care dispensing fees look like for long term
- 33:46Speaker 5: care pharmacies, and it's.
- 33:47Speaker 4: A wild range.
- 33:48Speaker 5: It ranges from twenty seven cents to eleven dollars and
- 33:52Speaker 5: ninety four cents depending on the state and the program
- 33:55Speaker 5: and the higher states the higher one that eleven ninety
- 33:57Speaker 5: four is in a state where the state requires the
- 34:01Speaker 5: same dispensing fees.
- 34:03Speaker 4: So what this legislation would do.
- 34:05Speaker 5: Is take that and make it federal, so all across
- 34:08Speaker 5: the America, and that would be a huge increase in
- 34:11Speaker 5: dispensing fees.
- 34:12Speaker 4: So that'd be a big win on the medicaid side.
- 34:14Speaker 5: Small part of the business for long term care pharmacies,
- 34:16Speaker 5: but a big win in the commercial space. That was
- 34:19Speaker 5: really the sticking point. The commercial stuff is more disclosure oriented,
- 34:23Speaker 5: and it runs to PBMs disclosing to employers, which seems
- 34:29Speaker 5: reasonable and you know, that seems like a good thing,
- 34:31Speaker 5: but not particularly relevant to us. So there's a long
- 34:35Speaker 5: way to go on PBM reform. Beyond that, I do
- 34:38Speaker 5: want to mention that one of the pieces of legislation
- 34:41Speaker 5: that I'm not sure survived into the ultimate package took
- 34:46Speaker 5: something that already exists right now. The Part D Statute
- 34:50Speaker 5: Guidance regulations have this thing called the any Willing Provider provision,
- 34:55Speaker 5: which means that any pharmacy that is willing to accept
- 34:58Speaker 5: the basic contract a plan is offer has to be
- 35:00Speaker 5: allowed into the network. But those contracts generally are terrible,
- 35:05Speaker 5: and CMS historically has said, well, if a contract, if
- 35:10Speaker 5: a pharmacy accepts a contract, then it must be reasonable,
- 35:15Speaker 5: which is of course ridiculous if you understand the market dynamics,
- 35:17Speaker 5: sometimes you have no choice. You either participate and lose
- 35:21Speaker 5: money but keep the business of your retail pharmacy on
- 35:24Speaker 5: the front end of the store, or you know, you
- 35:27Speaker 5: can't survive. So Congress in this legislation would have given
- 35:32Speaker 5: some teeth to that provision, right, and would have required
- 35:36Speaker 5: actual regulatory standards on what it meant to have reasonable
- 35:41Speaker 5: and relevant contract terms Congress, So that was one thing.
- 35:45Speaker 5: But interestingly, and I think in part because of all
- 35:47Speaker 5: of this, when CMS published the regulation this year for
- 35:52Speaker 5: the twenty twenty six that it's called the payment Rule,
- 35:54Speaker 5: but basically every year they tell the plans what they're
- 35:57Speaker 5: going to do differently, you know, and it's it's a
- 36:00Speaker 5: regulation subject to public comment, etc. And it also has
- 36:03Speaker 5: provisions that are relevant to us. One of the things
- 36:06Speaker 5: they asked is for input. It's kind of a request
- 36:09Speaker 5: for information input on how they should go about giving
- 36:14Speaker 5: teeth to this provision that already exists, right, and the
- 36:19Speaker 5: term of artists is reasonable and relevant contract terms, So
- 36:21Speaker 5: what should they consider? And what we did is we
- 36:24Speaker 5: have like a twenty page submission where we listed all
- 36:29Speaker 5: of these abuses that our members had identified, categorized them,
- 36:33Speaker 5: and made suggestions about how to create reasonable and relevant
- 36:38Speaker 5: contract terms that prevent these kind of abusive practice.
- 36:41Speaker 4: From practices from happening.
- 36:43Speaker 5: And we are now working with mister Carter who I
- 36:45Speaker 5: mentioned are those in Congress to put pressure on CMS
- 36:49Speaker 5: to now publish regulations that speak proposed regulations for public
- 36:54Speaker 5: comment that try to define those contract terms, so that
- 36:58Speaker 5: I think has some real promise for us. That's all
- 37:00Speaker 5: part D long way to go, but I think real progress.
- 37:05Speaker 3: So what actions can LTC pharmacies take to advocate for
- 37:10Speaker 3: meaningful PM reform.
- 37:13Speaker 4: Right now? Yeah?
- 37:15Speaker 5: I think I think the thing to do is to
- 37:16Speaker 5: contact your members of Congress and we can help you
- 37:18Speaker 5: do that if you're members, and even if you're not
- 37:20Speaker 5: talk to me, you know, to say we need PBM reform,
- 37:25Speaker 5: We need this stuff right now, and we need more
- 37:27Speaker 5: and it needs and we need some long term care
- 37:29Speaker 5: pharmacy specific reforms because some of these issues inflect differently
- 37:35Speaker 5: for us than they do for retail. For example, this
- 37:39Speaker 5: reasonable and relevant contract terms, well because we have because
- 37:42Speaker 5: there's a separate long term care pharmacy network atticy requirements.
- 37:47Speaker 5: You know, contract terms are different. That's that is why
- 37:50Speaker 5: there's a higher dispensing fee and skilled nursing facilities than
- 37:53Speaker 5: there is in retail because of that provision. So how
- 37:57Speaker 5: do we make sure that these reasonable and relevant contract
- 38:00Speaker 5: terms take that into account. We obviously argued for that
- 38:03Speaker 5: in our comments. We tried to get that provision changed,
- 38:07Speaker 5: but unsuccessfully.
- 38:10Speaker 4: And because because basically.
- 38:12Speaker 5: CMS said, we have you know, we would be able
- 38:14Speaker 5: to do that anyway, and we can exercise discretion to
- 38:17Speaker 5: do it, but I'd rather have Congress talent to do
- 38:19Speaker 5: it than fight with CMS about it, right, So so
- 38:22Speaker 5: really what you can do is you can get involved.
- 38:24Speaker 5: That's that's the bottom line. Get involved. An ideal world,
- 38:27Speaker 5: you join SEPC, if you're not already a member, whether
- 38:30Speaker 5: you are or you're not, you'd find ways to engage
- 38:32Speaker 5: with your Members of Congress, not only you know, writing
- 38:35Speaker 5: emails and that sort of stuff, but inviting them into
- 38:38Speaker 5: your pharmacy, trying to get them to understand how long
- 38:41Speaker 5: term care pharmacy is different from retail pharmacy and why
- 38:44Speaker 5: you need separate solutions and separate and you know, and
- 38:47Speaker 5: really get them aware not only on the PDM side,
- 38:51Speaker 5: but also on the on the you know, on the
- 38:53Speaker 5: drug pricing side, and set it up for the future.
- 38:56Speaker 3: You've referenced a few times in this discussion a few
- 38:59Speaker 3: data elements, you know, specifically around the margin rates that
- 39:03Speaker 3: will be eroded with some of the pending legislation or
- 39:07Speaker 3: just current state of things with Inflation Reduction Act. How
- 39:11Speaker 3: important is having quantifiable you know, data elements as you're
- 39:15Speaker 3: as you're having that conversation with Members of Congress and
- 39:20Speaker 3: submitting your written responses and feedback. How important is that
- 39:24Speaker 3: data to the success of your efforts? And it's crucial,
- 39:29Speaker 3: you know, in Washington. First of all, when you walk
- 39:32Speaker 3: into a Member of Congress's office, anecdotes are great, but
- 39:36Speaker 3: to persuade policymakers and especially to pertray at CMS.
- 39:40Speaker 4: You need data.
- 39:41Speaker 5: And if you have opponents, let's just say PBM opponents, right,
- 39:46Speaker 5: something beats nothing, and they're going to have all sorts
- 39:48Speaker 5: of analysis, you know, and so it's important that you
- 39:52Speaker 5: have it. And it's important in my view that it'd
- 39:54Speaker 5: be credible. A lot of the stuff that gets spewed
- 39:57Speaker 5: out is not methodologically sound, it's not statistically reliant, statistically
- 40:03Speaker 5: you know, significant, and it can eat and you will
- 40:09Speaker 5: lose credibility, which is why we structure our data and
- 40:12Speaker 5: you know, with third party researchers. One of the challenges
- 40:17Speaker 5: in the pharmacy space and the long term care pharmacy
- 40:19Speaker 5: space is there is limited publicly available data. There are
- 40:23Speaker 5: some databases you can purchase, and that's fine. We do
- 40:26Speaker 5: or or you know, consultants do. But a lot of
- 40:30Speaker 5: what we do is gathering data from our members, which
- 40:32Speaker 5: is a second reason why it's so important that we
- 40:34Speaker 5: use third parties because we do not We as SEPC,
- 40:38Speaker 5: do not want to know any details about individual members.
- 40:41Speaker 5: We don't want to report based on individual member data,
- 40:45Speaker 5: so we use third parties. The data doesn't go to us,
- 40:48Speaker 5: it goes to them. We're prevented from seeing individual pharmacy information.
- 40:52Speaker 4: It's only used in the aggregate so aside. But you
- 40:56Speaker 4: need analytics.
- 40:57Speaker 5: It needs to be sound and credible, and you need
- 41:00Speaker 5: to be able to explain it if asked, and without data,
- 41:05Speaker 5: it is very hard to drive policy in this arena,
- 41:08Speaker 5: you know, And the breadth and.
- 41:12Speaker 3: The level of commitment of of your membership and of
- 41:15Speaker 3: the broader OUTC community will just improve the quality and
- 41:20Speaker 3: impact that that data can have. You need more people
- 41:22Speaker 3: involved exact some point.
- 41:23Speaker 5: Absolutely, as you know Scott better than anybody probably listening
- 41:28Speaker 5: to this.
- 41:29Speaker 4: You know what it costs to do data?
- 41:31Speaker 3: Well, that's right.
- 41:32Speaker 5: You know it is not cheap, but it is it
- 41:34Speaker 5: is sufficiently valuable that it's worth it. And there is
- 41:39Speaker 5: huge ROI from investing in in you know, good data
- 41:43Speaker 5: systems and good data.
- 41:46Speaker 3: Absolutely, it's a huge focus for soft writers. In the
- 41:48Speaker 3: year I had years ahead, I should say, so change
- 41:52Speaker 3: change gears a little bit. So we talked about some
- 41:54Speaker 3: of the pressure on facilities. We know that there's been
- 41:58Speaker 3: a not so recent trend of patients wanting to age
- 42:02Speaker 3: at home, and so talk a little bit about there's
- 42:05Speaker 3: the Alliance for LTC Pharmacy at Home and how is
- 42:09Speaker 3: that helping pharmacies and can you just talk a little
- 42:11Speaker 3: bit about that demandat there.
- 42:14Speaker 5: Yeah, you know, the first thing I would say is that,
- 42:17Speaker 5: you know, the next person I meet who wants to
- 42:19Speaker 5: be in a long term care facility will be the
- 42:21Speaker 5: first person I have ever met wants to be in
- 42:23Speaker 5: a long term care facility. You know, of course you
- 42:26Speaker 5: still need to have them, and like if you just
- 42:29Speaker 5: look at the Medicare population, they're a little over four
- 42:32Speaker 5: million Medicare beneficiaries who need long term care. Three quarters
- 42:36Speaker 5: of them already live at home. Right, So there's this
- 42:40Speaker 5: huge and growing population of folks who need long term care,
- 42:43Speaker 5: who are living at home or in the community and
- 42:46Speaker 5: who want to stay there. Some will not be able to,
- 42:48Speaker 5: but a lot will, and we across the board do
- 42:51Speaker 5: not have an adequate service delivery system for them in the.
- 42:56Speaker 4: Long term care pharmacy space.
- 42:57Speaker 5: This is what the Alliance for Long Term Care Pharmacy
- 42:59Speaker 5: at Home is trying to do, is trying to improve
- 43:01Speaker 5: access to long term care pharmacy services at home. And effectively,
- 43:05Speaker 5: what it comes down to when you cut through all
- 43:07Speaker 5: the rhetoric is how do we make sure how do
- 43:11Speaker 5: we get long term care pharmacies or pharmacies that provide
- 43:13Speaker 5: those services to people at home to get paid for
- 43:16Speaker 5: those services, or at least get paid the dispensing fee
- 43:19Speaker 5: that long term care pharmacies get in skilled nursing.
- 43:23Speaker 4: And in order to understand what the Alliance is.
- 43:25Speaker 5: Trying to do, you have to understand how that works,
- 43:27Speaker 5: and essentially it's not required people think it is. CMS
- 43:31Speaker 5: has created a series of incentives for plans to pay
- 43:35Speaker 5: higher dispensing fees. They've created separate long term care pharmacy
- 43:38Speaker 5: network adequacy requirements which enumerate the various characteristics that a
- 43:42Speaker 5: pharmacy has to have to be included in proving to
- 43:46Speaker 5: CMS that a plan has long term care pharmacy network adequacy.
- 43:50Speaker 5: These are the things that we're all familiar with, and
- 43:53Speaker 5: that and a few other things kind of have made
- 43:57Speaker 5: PBMs and plans say, you know what, we need to
- 44:00Speaker 5: pay higher dispensing fees because we don't want to get
- 44:02Speaker 5: crosswise with CMS. If we don't have long term care
- 44:05Speaker 5: pharmacy network adequacy, we lose our party contract entirely.
- 44:09Speaker 4: It's not just we lose the long term care fees.
- 44:11Speaker 5: And so we don't want to put ninety five percent
- 44:14Speaker 5: of our business at risk to get a few bucks
- 44:16Speaker 5: on a dispensing fee for five percent of our business.
- 44:19Speaker 4: But those requirements don't apply.
- 44:21Speaker 5: Don't extend to assisted living, they don't extend to various
- 44:24Speaker 5: congregate living settings, and they certainly don't extend to people
- 44:27Speaker 5: at home. So the idea is to convince of the alliance,
- 44:31Speaker 5: is to convince CMS that they have the statutory authority
- 44:35Speaker 5: to do more than they have already done. To require
- 44:39Speaker 5: plans to kind of behave as if this was a
- 44:42Speaker 5: long term care pharmacy network adequacy thing, and to pay
- 44:44Speaker 5: higher dispensing fees, because if long term care pharmacies were
- 44:47Speaker 5: getting four or five bucks for providing services at home
- 44:51Speaker 5: instead of you know, twenty seven cents or thirty cents
- 44:54Speaker 5: or a buck, then that would expand access. And frankly,
- 44:58Speaker 5: if you expanded access at home, you would you would
- 45:01Speaker 5: keep more people at home, and you'd probably reduce overall
- 45:04Speaker 5: health care spending. Right because if you look at it,
- 45:07Speaker 5: people who are who need long term care are taking
- 45:11Speaker 5: twelve to fourteen prescriptions and interestingly, you know in sniffs
- 45:18Speaker 5: they're taking twelve and it's just a living they're taking fourteen.
- 45:22Speaker 5: And my theory is that that's because there's less effective
- 45:25Speaker 5: medication management it's issted living than there is in skilled
- 45:28Speaker 5: nursing because of these requirements.
- 45:30Speaker 4: So it's exploiting that kind of data, that kind of
- 45:33Speaker 4: sensibility and extending it to the at home world, as
- 45:37Speaker 4: well as constructing legal bases on which CMS can say,
- 45:39Speaker 4: you know what we can tell plents to do more?
- 45:42Speaker 3: Right? Right, Well, I think we've just reached time. Alan
- 45:47Speaker 3: you probably need a drink of water because you just
- 45:50Speaker 3: shared a whole host of really useful insights to us.
- 45:53Speaker 3: Thank you very much. This was just such an insightful
- 45:56Speaker 3: conversation and it's very apparent that you have expertise across
- 46:02Speaker 3: a wide range of issues, and we really appreciate your
- 46:06Speaker 3: advocacy and your leadership and in trying to drive uh,
- 46:10Speaker 3: you know, the LTC industry into the future.
- 46:14Speaker 4: Thank you, Scott.
- 46:14Speaker 5: I appreciate that, and I appreciate the opportunity to you know,
- 46:19Speaker 5: share some share some thoughts with the softwriter's constituency and I,
- 46:23Speaker 5: as always, it's a pleasure to spend an hour talking
- 46:26Speaker 5: with you.
- 46:27Speaker 3: Absolutely, So as we wrap up, I want to leave
- 46:29Speaker 3: our listeners with with a call to action. Whether you're
- 46:32Speaker 3: an LTC pharmacy leader, a broader healthcare provider, we're just
- 46:36Speaker 3: an advocate for senior care, stay informed and engaged in
- 46:39Speaker 3: these critical policy decisions that we discussed on you know
- 46:44Speaker 3: today around the IRA, the PBM reform, the LTC to
- 46:48Speaker 3: Home Alliance, and the best way to do this would
- 46:51Speaker 3: be to consider joining the Senior Care Pharmacy Coalition if
- 46:54Speaker 3: you're not already a member, and you can find more
- 46:56Speaker 3: information on the website for that for Senior Care Pharmacy
- 47:02Speaker 3: Coalition or their LinkedIn page. We will drop in the
- 47:05Speaker 3: show notes for today's discussion the links to those locations,
- 47:09Speaker 3: and of course, if you enjoyed this episode, don't forget
- 47:11Speaker 3: to subscribe to Framework Focus and thanks again for joining us,
- 47:14Speaker 3: Thank you to our listeners, and really, Alan, from the
- 47:17Speaker 3: bottom of my heart, I really appreciate your time today.
- 47:19Speaker 3: Look forward to seeing you next month in Orlando at
- 47:21Speaker 3: the SEPC MEETINGUM beating.
- 47:23Speaker 4: Thanks very much, Thank you, Scott